Targeting Microbiota 2018
Towards Clinical Revolution
Preliminary Agenda

October 28 - 30, 2018 - Porto, Portugal
www.microbiota-site.com
### Congress Sessions:
- Microbiota 2018: recent advances & challenges
- Recent analysis, methods, bioinformatics & interpretations
- Strategic role of metabolites and mediators on the microbiota-host cross-talk
- Strategies to manipulate microbiota & medicine of tomorrow

### Call for Abstracts
- **Short Oral Submission**
  - Sept. 5, 2018
- **Poster Submission**
  - Sept. 27, 2018
- **Register & Save before**
  - Oct 02, 2018

### Microbiota 2018 Speakers

<table>
<thead>
<tr>
<th>Speaker</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yurdagül Zepf</td>
<td>Recent advances on gut microbiota and food intolerances</td>
</tr>
<tr>
<td>University of Erlangen-Nuremberg, Germany</td>
<td></td>
</tr>
<tr>
<td>Paul Forsythe</td>
<td>Psycho neuro immunology and gut microbes</td>
</tr>
<tr>
<td>McMaster University, Canada</td>
<td></td>
</tr>
<tr>
<td>Jan Mazela</td>
<td>Targeted gut microbiota and short chain fatty acid profile among term and preterm infants</td>
</tr>
<tr>
<td>Poznan University of Medical Sciences, Poland</td>
<td></td>
</tr>
<tr>
<td>Markus Egert</td>
<td>Honor thy lodgers? Interactions between the built environment microbiome and the human microbiome</td>
</tr>
<tr>
<td>Furtwangen University, Germany</td>
<td></td>
</tr>
<tr>
<td>Mohammadali Khan Mirzaei</td>
<td>Phage therapy strategy to modulate the child stunting microbiota</td>
</tr>
<tr>
<td>McGill University, Canada</td>
<td></td>
</tr>
<tr>
<td>Sara Federici</td>
<td>Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection</td>
</tr>
<tr>
<td>Weizmann Institute of Science, Israel</td>
<td></td>
</tr>
<tr>
<td>David Durgan</td>
<td>Exploring the role of gut dysbiosis in neuroinflammation and hypertension</td>
</tr>
<tr>
<td>Baylor College of Medicine, USA</td>
<td></td>
</tr>
<tr>
<td>Maria Vehreschild</td>
<td>Impact of antibiotic treatment on the human microbiota - a review of the clinical implications</td>
</tr>
<tr>
<td>University Hospital of Cologne, Germany</td>
<td></td>
</tr>
<tr>
<td>Ernst Holler</td>
<td>Role of microbes in stem cells transplantation related complication</td>
</tr>
<tr>
<td>University Hospital Regensburg, Germany</td>
<td></td>
</tr>
<tr>
<td>Antonio Riva</td>
<td>MAIT cells (Mucosal-Associated Invariant T cells) in liver disease and antibacterial response</td>
</tr>
<tr>
<td>Institute of Hepatology London, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>Marcin Utnal</td>
<td>The effect of gut bacterial metabolites on cardiovascular risk</td>
</tr>
<tr>
<td>Medical University of Warsaw, Poland</td>
<td></td>
</tr>
<tr>
<td>Julien Diana</td>
<td>Crosstalk between gut microbiota, innate immune cells and endocrine cells in the pancreas regulates autoimmune diabetes</td>
</tr>
</tbody>
</table>
| Inserm, France
Dear Colleagues,

On behalf of the International Society of Microbiota, we are pleased to inform you that the 6th World Congress on Targeting Microbiota will be organized at Porto, Portugal, on October 28-30, 2018.

During both days, many oral and poster communications will be presented and will cover many hot topics:

- Microbiota 2018: Recent Advances & Perspectives
- Challenges of microbiota sequencing and analyzing: How to manage the Big Data of sequencing?
- Challenges of microbiota-host cross-talk understanding and intestinal microbiome signaling to extraintestinal organs
- Microbiota & medicine of tomorrow: Development of effective therapeutic strategies to manipulate the gut microbiota

During Targeting Microbiota 2018, we will try to answer many question, among them:

- Can we modulate the quality and diversity of human microbiota?
- How to induce durable beneficial changes in gut microbiota?
- Where is the red line of the gut microbiota manipulation?
- What are the strategic mediators of gut microbiota?
- How to understand better the role of bacterial metabolites?
- What is the perfect microbiota "signature" and how to use it as a biomarker to "predict" and/or treat many diseases?
- What is the influence of gut microbiota on the development and progression of chronic diseases?

I do believe that this would be the best future strategy for the 6th World Congress of Targeting Microbiota in 2018: a strong communication between basic, pre-clinical scientists and clinicians.

**Microbiota & Medicine of Tomorrow: The Revolution**

The scientific committee of ISM and in particular Prof. Marvin Edeas (Institut Cochin, Université Paris Descartes, France), founder of the International Society of Microbiota (ISM) wish to highlight: "...there is a deep transformation in our current medicine where big data and Artificial Intelligence will play a strategic role in the medicine of tomorrow. How all big data generated by microbiota sequencing can be used? Can we talk about Artificial Intelligence and microbiota medicine? We wish to open the door for this kind of discussion..."

So, I hope to meet you at the next meeting in order to capture moments of relationship and scientific inspirations by the many and best scientists we have in the world studying the various aspects of the microbiota.

We very much look forward to seeing you in Berlin for this exciting event.

Prof. Peter C. Konturek - President of ISM
Teaching Hospital of the University of Jena, Germany
President of the International Society of Microbiota
Scientific Preliminary Agenda

Day 1 – Sunday, October 28

17h00 – 18h00  Registration – Badges & Material Providing

Day 2 – Monday, October 29

7h45  Welcoming & registration of attendees

8h55  Introduction note by President of ISM Targeting Microbiota 2018
Peter Konturek, Teaching Hospital of the University of Jena, Germany

Session 1: Microbiota 2018: Recent Advances & Challenges  
9h00 – 15h40

Honor the lodgers? – Interaction between the built environment microbiome and the human microbiome (Skin & Gut)
Markus Egert, Furtwangen University, Germany

Impact of Antibiotics and microbiota: recent scientific advances and perspectives
Maria Vehreschild, University Hospital of Cologne, Germany

Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection
Sara Federici, Weizmann Institute of Science, Israel

Recent advances on gut microbiota and food intolerances
Yurdagül Zopf, University of Erlangen-Nuremberg, Germany

Exploring the role of gut dysbiosis in neuroinflammation and hypertension
David Durgan, Baylor College of Medicine, USA

10h40  Coffee Break & Poster Session

Role of microbes in stem cells transplantation related complication
Ernst Holler, University Hospital Regensburg, Germany

12h45  Lunch Break, Network & Poster Session

Short oral presentations for sessions 1 (7 minutes presentation + 3 minutes questions)

15h40  Coffee Break, Network & Poster Session

Session 2: Microbiota recent analysis and methods, bioinformatics & interpretations
16h25 – 16h30

18h00  End of the day

20h30  Targeting Microbiota Dinner
Day 3 – Tuesday, October 30

8h55 Opening of the second day

Session 3: Strategic role of metabolites and mediators on the microbiota-host cross-talk
9h00 – 12h45

Crosstalk between gut microbiota, innate immune cells and endocrine cells in the pancreas regulates autoimmune diabetes
Julien Diana, Institut National de la Santé et de la Recherche Médicale (INSERM), France

MAIT cells (Mucosal-Associated Invariant T cells) in liver disease and antibacterial response
Antonio Riva, Institute of Hepatology London, Foundation for Liver Research, United Kingdom

The effect of gut bacterial metabolites on cardiovascular risk
Marcin Ufnal, Medical University of Warsaw, Poland

Psycho neuro immunology and gut microbes
Paul Forsythe, McMaster University, Canada

Targeted gut Microbiota and short chain fatty acid profile among term and preterm infants
Jan Mazela, Poznan University of Medical Sciences, Poland

Current and new approaches for measuring gut-blood barrier permeability
Kinga Jaworska, Medical University of Warsaw, Poland

10h40 Coffee Break, Network & Poster Session

Short oral presentations (7 minutes presentation + 3 minutes questions)

12h45 Lunch Break, Network & Poster Session

Session 4: Strategies to manipulate microbiota & medicine of tomorrow
This session is focused on effective therapeutic strategies to manipulate gut microbiota including phage therapy, pre- & probiotics treatments, and fecal microbiota transplant (FMT)
14h00 – 17h15

Fecal Microbiota Transplant 2018: What’s next?
Prof. Peter Konturek, Teaching Hospital of the University of Jena, Germany

Phage therapy strategy to modulate the child stunting microbiota
Mohammadali Khan Mirzaei, McGill University, Canada

15h40 Coffee Break & Poster Session

Short oral presentations (7 minutes presentation + 3 minutes questions)

Altered gut microbiota and endocannabinoid system tone in vitamin D deficiency-mediated chronic pain
Francesca Guida, Università degli Studi della Campania “Luigi Vanvitelli”, Italy

General discussion & Concluding remarks:

Targeting Microbiota 2018 Awards

18h00 End of Targeting Microbiota 2018